All In Biotech

Drug Trial Radar · NCT03790111

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Last checked: Nov 20, 2026Latest source record: Apr 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

53

Actual

Start

Mar 13, 2019

Primary completion

Jan 13, 2022

Study completion Jan 13, 2022

Sponsor

Lead sponsor
TerSera Therapeutics LLCIndustry
Sponsor type
Industry
First posted
Dec 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin \[cis\] plus gemcitabine \[gem\])

Conditions

  • Biliary Tract Cancer (BTC)

Interventions

  • telotristat ethylDrug

    XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's AssessmentTime frame: Month 6
  2. Project Overall Survival Rate at Month 6Time frame: 6 Months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • TerSera Investigational Site

    Gilbert, Arizona

  • TerSera Investigational Site

    Fullerton, California

  • TerSera Investigational Site

    Gainesville, Florida

  • TerSera Investigational Site

    Tampa, Florida

  • TerSera Investigational Site

    Chicago, Illinois

  • TerSera Investigational Site

    Westwood, Kansas

  • TerSera Investigational Site

    Lexington, Kentucky

  • TerSera Investigational Site

    Boston, Massachusetts

  • TerSera Investigational Site

    Grand Rapids, Michigan

  • TerSera Investigational Site

    Buffalo, New York

  • TerSera Investigational Site

    Lake Success, New York

  • TerSera Investigational Site

    Charlotte, North Carolina

  • TerSera Investigational Site

    Oklahoma City, Oklahoma

  • TerSera Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.